TRVN - Trevena Inc Stock Price, Fair Value and News

$1.78+0.13 (+7.88%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TRVN Price Action

Last 7 days

-9.2%

Last 30 days

-12.9%

Last 90 days

-75.1%

Trailing 12 Months

-90.2%

TRVN RSI Chart

TRVN Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.05

Price/Sales (Trailing)

0.55

EV/EBITDA

-0.47

Price/Free Cashflow

-0.06

TRVN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TRVN Fundamentals

TRVN Revenue

Revenue (TTM)

3.1M

Rev. Growth (Yr)

57.22%

Rev. Growth (Qtr)

-12.92%

TRVN Earnings

Earnings (TTM)

-34.0M

Earnings Growth (Yr)

37.72%

Earnings Growth (Qtr)

-0.98%

TRVN Profitability

Operating Margin

49.26%

EBT Margin

-1435.07%

Return on Equity

145.94%

Return on Assets

-177.28%

Free Cashflow Yield

-1.8K%

TRVN Investor Care

Shares Dilution (1Y)

42.32%

Diluted EPS (TTM)

-48.36

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	2.1M	2.6M	3.1M
2022	1.1M	1.6M	0	0
2021	3.3M	3.5M	637.0K	567.0K
2020	4.7M	4.1M	3.6M	3.1M
2019	0	0	0	5.2M
2018	0	4.4M	5.5M	5.7M
2016	7.5M	7.5M	5.6M	3.8M
2015	1.6M	3.0M	4.4M	6.3M
2013	339.4K	271.3K	203.1K	135.0K
2012	0	0	0	407.6K

Get all data in R, Python etc through our Historical Stock Data APIs

About Trevena Inc

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

CEO	Ms. Carrie L. Bourdow
WEBSITE	trevena.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	35

Trevena Inc Frequently Asked Questions

What is the ticker symbol for Trevena Inc? What does TRVN stand for in stocks?

TRVN is the stock ticker symbol of Trevena Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Trevena Inc (TRVN)?

As of Thu Dec 19 2024, market cap of Trevena Inc is 1.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TRVN stock?

You can check TRVN's fair value in chart for subscribers.

Is Trevena Inc a good stock to buy?

The fair value guage provides a quick view whether TRVN is over valued or under valued. Whether Trevena Inc is cheap or expensive depends on the assumptions which impact Trevena Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TRVN.

What is Trevena Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 19 2024, TRVN's PE ratio (Price to Earnings) is -0.05 and Price to Sales (PS) ratio is 0.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TRVN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Trevena Inc's stock?

In the past 10 years, Trevena Inc has provided -0.53 (multiply by 100 for percentage) rate of return.